实用肿瘤杂志2011，Vol.26Issue(1)：55-58,4.
姑息化疗EGFR-TKI治疗失败后晚期非小细胞肺癌临床疗效观察
Clinical observation of palliative chemotherapy for 16 patients with advanced non-small cell lung cancer failed in treatment of EGFR-TKI
杨军礼 1张秀春 1袁霞妹 1楼君 1黄曙1
作者信息
- 1. 金华广福医院肿瘤内和,浙江,金华,321000
- 折叠
摘要
Abstract
Objective To observe the efficacy and toxicity of palliative chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) failed in the treatment of EGFR-TKI. Methods Sixteen patients with advanced NSCLC failed in the treatment of EGFR-TKI were divided into two groups. Ten cases received combination chemotherapy and 6 cases were treated with single-agent chemotherapy. Results Among the 16 patients with advanced NSCLC failed in the treatment of EGFR-TKI, partial response (PR) accounted for 6.25％; stable disease ( SD ) accounted for 62. 5％; disease control rate accounted for 68. 8％. In combination chemotherapy group, the median survival time was 13 months; 1-year survival rate was 60.0％. In single-agent chemotherapy groups,the median survival time was 8 months; 1-year survival rate was 33.3％. There was no significant difference between the two groups (P＞ 0.05). In two groups, the toxicities were mild and tolerable. Conclusion Treatment with palliative chemotherapy for patients with advanced NSCLC who fails in the treatment of EGFR-TKI and has a good physical strength condition might be feasible.关键词
癌,非小细胞肺/EGFR-TKI/药物疗法/姑息疗法分类
医药卫生引用本文复制引用
杨军礼,张秀春,袁霞妹,楼君,黄曙..姑息化疗EGFR-TKI治疗失败后晚期非小细胞肺癌临床疗效观察 [J].实用肿瘤杂志,2011,26(1):55-58,4.
